ReNeuron Group - Biblical aspirations
ReNeuron’s interim results for the six months to 30 September 2017 showcased a crucial juncture in the company’s history. With the first of two US...
53 Views
Milestones expected as pipeline progresses
The highlight of FY17 was positive Phase II efficacy data from ReNeuron’s PISCES II clinical trial. As this and its other clinical programmes in...
97 Views
Global clinical pipeline strategy update
ReNeuron continues to prepare for its Phase III chronic stroke study (due to start in H217) and has indicated that it is making progress with the...
72 Views
Clinical pipeline progressing as planned
ReNeuron reported in December 2016 positive Phase II trial data for its CTX cells in chronic stroke patients, despite not meeting the three-month...
64 Views
Positive Phase II stroke data
ReNeuron has presented positive Phase II trial data for its CTX cells in chronic stroke patients. Reported data included 15 out of 21 patients...
87 Views
No more insights